Sei Naito

2.1k citations

101 papers · 1.4k · h-index 18

Impact in

Cancer Research top 5%
- Cancer Genomics and Diagnostics
Pulmonary and Respiratory Medicine top 5%
- Renal cell carcinoma treatment

Papers in

Pulmonary and Respiratory Medicine 62
- Renal cell carcinoma treatment 48
Molecular Biology 34
- Renal and related cancers 21
- Wnt/β-catenin signaling in development and cancer 5

Co-authors: Yoshihiko Tomita (17 shared papers)Hideyuki Akaza (14 shared papers)Tomoyuki Kato (36 shared papers)Vladimir Bilim (7 shared papers)Tadashi Tsukamoto (4 shared papers)Kaori Yuuki (6 shared papers)Akira Nagaoka (14 shared papers)Masaru Murai (2 shared papers)
Journals: International Journal of Urology (11 papers)Japanese Journal of Clinical Oncology (10 papers)Journal of Clinical Oncology (9 papers)International Journal of Clinical Oncology (5 papers)BMC Cancer (4 papers)
Partner nations: Japan United States South Korea

In The Last Decade

Sei Naito

92 papers receiving 1.4k citations

Peers

Countries citing papers authored by Sei Naito

Since Specialization

Citations

This map shows the geographic impact of Sei Naito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sei Naito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sei Naito more than expected).

Fields of papers citing papers by Sei Naito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sei Naito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sei Naito. The network helps show where Sei Naito may publish in the future.

Co-authors

The 25 scholars most cited alongside Sei Naito, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sei Naito Line = papers co-authored together Sei Naito links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 101 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma Japanese Journal of Clinical Oncology ·Hideyuki Akaza, Tadashi Tsukamoto, Masaru Murai, K. Nakajima, Sei Naito	2007	132
2	A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety Japanese Journal of Clinical Oncology ·Hirotsugu Uemura, Nozomi Shinohara, Takeshi Yuasa, Y. Tomita, Hiroshi Fujimoto, Masashi Niwakawa, Soichi Mugiya, T Miki, Norio Nonomura, Masayuki Takahashi, Y. Hasegawa, Naoki Agata, Brett A. Houk, Sei Naito, Hideyuki Akaza	2009	119
3	Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma Japanese Journal of Clinical Oncology ·Yoshihiko Tomita, Nobuo Shinohara, Takeshi Yuasa, Hiroshi Fujimoto, Masashi Niwakawa, Soichi Mugiya, Takahiro Miki, Hirotsugu Uemura, Norio Nonomura, Masayuki Takahashi, Yoshihiro Hasegawa, Naoki Agata, Brett E. Houk, Sei Naito, Hideyuki Akaza	2010	100
4	Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma British Journal of Cancer ·Vladimir Bilim, Andrei V. Ougolkov, Kaori Yuuki, Sei Naito, Hisashi Kawazoe, Andrea Muto, Mototsugu Oya, Daniel D. Billadeau, Teiichi Motoyama, Yoshihiko Tomita	2009	92
5	Glycogen Synthase Kinase-3β: A Prognostic Marker and a Potential Therapeutic Target in Human Bladder Cancer Clinical Cancer Research ·Sei Naito, Vladimir Bilim, Kaori Yuuki, Andrey Ugolkov, Teiichi Motoyama, Akira Nagaoka, Tomoyuki Kato, Yoshihiko Tomita	2010	72
6	Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3β Cancer Letters ·Masaaki Tsukigi, Vladimir Bilim, Kaori Yuuki, Andrey Ugolkov, Sei Naito, Akira Nagaoka, Tomoyuki Kato, Teiichi Motoyama, Yoshihiko Tomita	2011	72
7	Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial Japanese Journal of Clinical Oncology ·Takeshi Ueda, Hirotsugu Uemura, Y. Tomita, Tadashi Tsukamoto, Hiro-omi Kanayama, Nobuo Shinohara, Jamal Tarazi, C. Chen, Seungchan Kim, S. Ozono, Sei Naito, Hideyuki Akaza	2013	67
8	Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected by J-CaP Japanese Journal of Clinical Oncology ·Shiro Hinotsu, Hideyuki Akaza, M Usami, Osamu Ogawa, Shunsuke Kagawa, Tadaichi Kitamura, Tadashi Tsukamoto, Sei Naito, Mikio Namiki, Y. Hirao, Masaru Murai, Hisashi Yamanaka, (unknown)	2007	53
9	Kidney Cancer Working Group Report Japanese Journal of Clinical Oncology ·Sei Naito, Y. Tomita, Sun Young Rha, Hirotsugu Uemura, Mototsugu Oya, Hang Song, Luhui Zhong, M. I. B. A. Wahid	2010	44
10	The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma Cell Death and Disease ·Peter Makhov, Sei Naito, Miki Haifler, Alexander Kutikov, Yanis Boumber, Robert G. Uzzo, Vladimir Kolenko	2018	40
11	GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC) Biochemical and Biophysical Research Communications ·Hisashi Kawazoe, Vladimir Bilim, Andrey Ugolkov, Kaori Yuuki, Sei Naito, Akira Nagaoka, Tomoyuki Kato, Yoshihiko Tomita	2012	38
12	Prognostic Factors of Patients With Metastatic Renal Cell Carcinoma With Removed Metastases: A Multicenter Study of 556 Patients Urology ·Sei Naito, Hidefumi Kinoshita, Tsunenori Kondo, Nobuo Shinohara, Takashi Kasahara, Kazutaka Saito, Tatsuya Takayama, Naoya Masumori, Wataru Takahashi, Masayuki Takahashi, Toshiro Terachi, Seiichiro Ozono, Seiji Naito, Yoshihiko Tomita	2013	37
13	GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition BMC Cancer ·Hiromi Ito, Osamu Ichiyanagi, Sei Naito, Vladimir Bilim, Yoshihiko Tomita, Tomoyuki Kato, Akira Nagaoka, Norihiko Tsuchiya	2016	37
14	Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma Cancer Biology & Therapy ·Konstantin Golovine, Peter Makhov, Sei Naito, Henish K. Raiyani, Jeffrey Tomaszewski, Reza Mehrazin, Alexei V. Tulin, Alexander Kutikov, Robert G. Uzzo, Vladimir Kolenko	2015	33
15	LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma British Journal of Cancer ·Sei Naito, Peter Makhov, Igor Astsaturov, Konstantin Golovine, Alexei V. Tulin, Alexander Kutikov, Robert G. Uzzo, Vladimir Kolenko	2017	29
16	Clinical relevance of seasonal changes in the prevalence of ureterolithiasis in the diagnosis of renal colic Urolithiasis ·Hiroki Fukuhara, Osamu Ichiyanagi, Hiroshi Kakizaki, Sei Naito, Norihiko Tsuchiya	2016	22
17	Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular‐targeted therapy Cancer Science ·Nobuo Shinohara, Wataru Obara, Katsunori Tatsugami, Sei Naito, Tomomi Kamba, Masayuki Takahashi, Sachiyo Murai, Takashige Abe, Koji Oba, Seiji Naito	2015	21
18	Bacillus Calmette-Guerin and BCG cell wall skeleton suppressed viability of bladder cancer cells in vitro. PubMed ·Tomoyuki Kato, Vladimir Bilim, Kaori Yuuki, Sei Naito, Takuya Yamanobe, Akira Nagaoka, Ikuya Yano, Hideyuki Akaza, Yoshihiko Tomita	2010	19
19	Reinforcement of the Triple D score with simple addition of the intrarenal location for the prediction of the stone-free rate after shockwave lithotripsy for renal stones 10–20 mm in diameter International Urology and Nephrology ·Osamu Ichiyanagi, Hiroki Fukuhara, Masayuki Kurokawa, Takuji Izumi, Hitoshi Suzuki, Sei Naito, Hayato Nishida, Tomoyuki Kato, Norihiko Tsuchiya	2019	14
20	Combined Immunotherapy with Low-dose IL-2 Plus IFN- for Metastatic Renal Cell Carcinoma: Survival Benefit for Selected Patients with Lung Metastasis and Serum Sodium Level Japanese Journal of Clinical Oncology ·Hideyuki Akaza, Tadashi Tsukamoto, Tomoaki Fujioka, Yoshihiko Tomita, Tadaichi Kitamura, S. Ozono, Takahiro Miki, Sei Naito, Hitoshi Zembutsu, Yousuke Nakamura	2011	14

About Sei Naito

Sei Naito is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, Surgery and Oncology, having authored 101 papers that have together received 1.4k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (48 papers), Cancer Genomics and Diagnostics (23 papers), Renal and related cancers (21 papers), Cancer Immunotherapy and Biomarkers (16 papers), Bladder and Urothelial Cancer Treatments (15 papers), Multiple and Secondary Primary Cancers (7 papers), Economic and Financial Impacts of Cancer (6 papers) and Wnt/β-catenin signaling in development and cancer (5 papers). The work is most often cited by research in Cancer Research (405 citations), Pulmonary and Respiratory Medicine (794 citations), Oncology (399 citations), Molecular Biology (749 citations) and Nephrology (26 citations). Sei Naito has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Yoshihiko Tomita, Hideyuki Akaza, Tomoyuki Kato, Vladimir Bilim, Tadashi Tsukamoto, Kaori Yuuki, Akira Nagaoka, Masaru Murai, K. Nakajima and Norihiko Tsuchiya. Their work appears in journals such as International Journal of Urology, Japanese Journal of Clinical Oncology, Journal of Clinical Oncology, International Journal of Clinical Oncology and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Sei Naito

Impact in

Papers in i

In The Last Decade

Sei Naito

Peers

Countries citing papers authored by Sei Naito

Fields of papers citing papers by Sei Naito

All Works

About Sei Naito

Explore authors with similar magnitude of impact

Papers in